id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-352914-jccxzit1	Sanz Herrero, Francisco	Methylprednisolone added to tocilizumab reduces mortality in SARS‐CoV‐2 pneumonia: An observational study	2020-06-30		.txt	text/plain	1269	75	45	The guidelines for the treatment of SARS‐CoV‐2 pneumonia from the Spanish Ministry of Health contemplate the use of tocilizumab as a therapeutic tool for those patients with severe respiratory failure or rapid respiratory deterioration with criteria for admission to the intensive care unit (ICU). Although there are few randomized controlled trials (RCTs) evaluating the efficacy of drugs to treat COVID-19, different molecules have been used empirically and with great interest in those intended to control the excessive inflammatory response produced by SARS-CoV-2. The guidelines for the treatment of SARS-CoV-2 pneumonia from the Spanish Ministry of Health contemplate the use of tocilizumab as a therapeutic tool for those patients with severe respiratory failure or rapid respiratory deterioration with criteria for admission to the intensive care unit (ICU). We analyzed a population of 72 patients diagnosed with SARS-CoV-2 pneumonia using real-time reverse transcriptase-polymerase chain reaction who were treated with tocilizumab, of whom 77.8% (56 cases) also received treatment with methylprednisolone.	./cache/cord-352914-jccxzit1.txt	./txt/cord-352914-jccxzit1.txt